An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company called Bodybuilding Health+ released a review or report about their 2026 pricing and provider setup for a handful of injectable and IV therapies people are buying outside of standard prescriptions. The write-up highlights several products—GLP-1 drugs (the class that includes things like semaglutide), sermorelin (a growth-hormone–stimulating peptide), NAD+ (a molecule sometimes given by IV for energy claims), and tadalafil (a drug most know as Cialis). It also flags an important deadline from the FDA that affects anyone getting compounded versions of GLP-1 drugs. The piece is aimed at customers and people shopping for these services. When people talk about "GLP-1" drugs, they mean a class of medicines that copy a natural gut hormone. That hormone tells your brain you’re fuller sooner and slows how fast your stomach empties. GLP-1 drugs are used for diabetes and weight loss under brand names like Ozempic or Wegovy. Sermorelin isn’t the hormone itself but a small protein fragment that tells your body to release more growth hormone. NAD+ is a molecule cells use for energy, and some clinics give it by IV hoping it boosts energy and recovery—claims that aren’t strongly proven. Tadalafil is an approved medication for erectile dysfunction and other conditions and is well-studied when prescribed normally. The report seems to summarize what Bodybuilding Health+ charges, how they organize providers (for example, whether doctors or nurse practitioners oversee prescriptions), and it warns patients about an FDA deadline affecting compounded GLP-1 products. Compounded drugs are custom-made by a pharmacy rather than manufactured by big drug companies. The snippet doesn’t give study data or new clinical results; it’s about services, pricing, and regulatory timing. So there’s no new evidence here about health effects—just business and legal information that matters if you’re buying these treatments from a clinic that compounds medicines. Why this matters is practical. Many people are paying out of pocket for weight-loss or performance-related therapies and are comparing costs and oversight between clinics. If you get a compounded GLP-1 product—meaning a pharmacy mixed it up for you rather than it coming in a branded box—the FDA deadline could change availability or require different paperwork or supervision. That affects safety, price, and continuity of treatment. People using sermorelin, NAD+ IVs, or off-label tadalafil through clinics should know whether a licensed physician is evaluating them and whether the products are standard, branded medications or compounded versions. Be cautious: compounded medicines and clinic-created protocols can vary widely in quality and oversight. GLP-1 drugs approved by regulators have known dosing and safety profiles; compounded versions may not meet the same manufacturing standards. Sermorelin and NAD+ therapies have more limited evidence for the benefits many clinics claim, and they can have side effects or interact with other medications. Always check who is prescribing and supervising your treatment, ask for lab tests when appropriate, and confirm whether what you’re getting is an approved drug or a compounded product. If the FDA deadline applies to your clinic, ask how they’ll handle it so your treatment isn’t interrupted. Bottom line: This report is a buyer’s guide and regulatory heads-up, not new science—so if you’re using or considering these therapies, focus on provider oversight, product source (branded vs compounded), and how the FDA deadline might affect your care.
Source: ACCESS Newswire